Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review

Osimertinib, the third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard treatment for nonsmall cell lung cancer with EGFR mutation. However, osimertinib-induced interstitial lung disease (OsiILD) is considered to be a serious adverse event, so some pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wenyan, Zhang, Lijuan, Shen, Hui, Wang, Bin, Luo, Jiayou, Cui, Enhai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891277/
https://www.ncbi.nlm.nih.gov/pubmed/36373747
http://dx.doi.org/10.1097/CAD.0000000000001436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891277/
https://www.ncbi.nlm.nih.gov/pubmed/36373747
http://dx.doi.org/10.1097/CAD.0000000000001436

Ejemplares similares